Hisamitsu Pharmaceutical Co., Inc.

Tokyo Stock Exchange:4530.T

Sector

🏥 Health Care

Industries

💊 Drugstores & Retail Pharmacies

🔬 Clinical Trials

💊 Pharmaceuticals

🛍 Specialty Retail

💻 Telehealth

Location

Japan

Market Cap

USD 2.04 B

Share Price

USD 27.98

Avg Daily Volume

163,160

Change (1 day)

-0.18%

Change (1 year)

21.32%

Change (YTD)

7.50%

Hisamitsu Pharmaceutical Co., Inc. Operating Income Margin for the year ending February 28, 2025: 12.11%

Hisamitsu Pharmaceutical Co., Inc. Operating Income Margin is 12.11% for the year ending February 28, 2025, a 30.36% change year over year. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.

Hisamitsu Pharmaceutical Co., Inc. Operating Income Margin for the year ending February 29, 2024 was 9.29%, a 2.80% change year over year.
Hisamitsu Pharmaceutical Co., Inc. Operating Income Margin for the year ending February 28, 2023 was 9.04%, a 16.35% change year over year.
Hisamitsu Pharmaceutical Co., Inc. Operating Income Margin for the year ending February 28, 2022 was 7.77%, a -16.64% change year over year.
Hisamitsu Pharmaceutical Co., Inc. Operating Income Margin for the year ending February 28, 2021 was 9.32%, a -42.19% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Operating Income Margin	Gross Profit Margin	EBIT Margin	EBITDA Margin

Tokyo Stock Exchange: 4530.T

Hisamitsu Pharmaceutical Co., Inc.

CEO	Mr. Kazuhide Nakatomi
IPO Date	Jan. 1, 2001
Location	Japan
Headquarters	408, Tashiro Daikan-machi
Employees	2,759
Sector	🏥 Health Care
Industries Drugstores & Retail Pharmacies 🔬 Clinical Trials 💊 Pharmaceuticals 🛍 Specialty Retail 💻 Telehealth

Description

Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals, quasi-drugs, and medical devices in Japan. The company provides external pain relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; and BUTENALOCK, a remedy for athlete's foot, as well as ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, transdermal analgesic anti-inflammatory drug; patches for female hormone, asthma treatment, and treatment for overactive bladders. In addition, the company manufactures and sells drugs under MOHRUS TAPE, MOHRUS PAP XR, FENTOS Tapes, NEOXY Tapes, Abstral, ALLESAGA Tapes, HARUROPI Tapes, and MENOAID Combipatch. Further, it provides HFT-290, a transdermal patch for cancer pain. The company sells its products in the United States and Asia. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan.